Drug resistance

Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance

Friday, October 22, 2021 - 11:00am

REHOVOT, Israel, Oct. 22, 2021 (GLOBE NEWSWIRE) --  Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced a publication in Nature Cancer that provides new insight into the underlying mechanism of the therapeutic resistance of cancer cells and the significant role of insulin receptor substrate 1 (IRS1) pathway on epithelial growth factor receptor (EFGR) inhibition therapy. NT219, currently being evaluated in a Phase 1/2 clinical trial, is a novel small molecule inhibiting simultaneously IRS1/2 and STAT3.

Key Points: 
  • NT219, currently being evaluated in a Phase 1/2 clinical trial, is a novel small molecule inhibiting simultaneously IRS1/2 and STAT3.
  • The lead author of the publication is Ravid Straussman, M.D., Ph.D., Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • The article demonstrated mechanistic evidence of cancer cells' inherited therapeutic resistance, termed chance to persist (CTP).
  • Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies by overcoming tumor immune evasion and drug resistance.

Global Metastatic Breast Cancer Pipeline Insight Report 2021: Focus on 100+ Companies and 100+ Pipeline Drugs - ResearchAndMarkets.com

Monday, October 18, 2021 - 3:49pm

This "Metastatic Breast Cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape.

Key Points: 
  • This "Metastatic Breast Cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Breast Cancer R&D.
  • The therapies under development are focused on novel approaches to treat/improve Metastatic Breast Cancer.
  • This segment of the Metastatic Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

AnHeart Therapeutics Launches Study to Evaluate AXL inhibitor AB-329 in Metastatic Breast Cancer

Monday, October 18, 2021 - 1:00pm

AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapies, today announced sponsored research to evaluate AB-329, an AXL inhibitor in metastatic breast cancer.

Key Points: 
  • AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapies, today announced sponsored research to evaluate AB-329, an AXL inhibitor in metastatic breast cancer.
  • In breast cancer, AXL expression independently predicts poor overall patient survival.
  • We are excited to launch this study to evaluate AXL inhibitor AB-329 in metastatic breast cancer, an area of significant unmet medical need, said Bing Yan, M.D., MBA, Co-Founder & Chief Medical Officer, AnHeart.
  • There is an urgent unmet medical need to advance new therapeutic strategies for patients with metastatic triple-negative breast cancer and inflammatory breast cancer.

Global Peptide Therapeutics Marketplace 2021-2026: Key Applications, Drug Types, Types of Manufacturing, Synthesis Technologies, Regions & Players - ResearchAndMarkets.com

Thursday, October 14, 2021 - 9:46am

Since there is an increasing number of cancer patients, it is eventually increasing the prescription of peptide therapeutics to treat cancer.

Key Points: 
  • Since there is an increasing number of cancer patients, it is eventually increasing the prescription of peptide therapeutics to treat cancer.
  • As per the market by drug type, the innovative peptides segment has a significant share in the peptide therapeutics market.
  • Further, the market is based on the type of manufacturing; in this segmentation, the in-house manufacturing segment has a major contribution to the peptide therapeutics market share.
  • According to the synthesis technology, the liquid phase peptide synthesis (LPPS) segment has dominated the peptide therapeutics market share.

NYU Langone Health Launches Parekh Center for Interdisciplinary Neurology to Accelerate Scientific Discovery

Monday, October 11, 2021 - 2:00pm

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- NYU Langone Health announced today the launch of the Parekh Center for Interdisciplinary Neurology , made possible by a gift provided by Deven and Monika Parekh through the Psquared Charitable Foundation.

Key Points: 
  • NEW YORK, Oct. 11, 2021 /PRNewswire/ -- NYU Langone Health announced today the launch of the Parekh Center for Interdisciplinary Neurology , made possible by a gift provided by Deven and Monika Parekh through the Psquared Charitable Foundation.
  • The center helps bridge neuroscientific knowledge across the institution to advance scientific discovery and treatment of neurodegenerative conditions such as multiple sclerosis , Parkinson's disease , epilepsy , and others.
  • "The Parekh Center for Interdisciplinary Neurology will help unite physicians and researchers from different disciplines and fields to uncover effective, innovative interventions that may prevent or treat these debilitating conditions," says Un Jung Kang, MD , the Founders Professor of Neurology, professor of neuroscience and physiology, director of translational research at the Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders , and co-director of the Parekh Center for Interdisciplinary Neurology at NYU Langone Health.
  • "Funding these early-stage, innovative, and interdisciplinary approaches to the study of neurodegenerative diseases can be challenging for researchers," says Monika Parekh.

Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Thursday, October 7, 2021 - 2:00pm

These results reinforce the broad potential of autophagy inhibition as a mechanism to address the challenge of drug resistance in the treatment of cancer.

Key Points: 
  • These results reinforce the broad potential of autophagy inhibition as a mechanism to address the challenge of drug resistance in the treatment of cancer.
  • The poster presentation is available on-demand via the meeting website and on the Companys website at www.deciphera.com/presentations-publications .
  • Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.
  • Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.

LexaGene’s Largest Study Validates Accuracy of its Veterinary Test Panel

Thursday, October 7, 2021 - 12:45pm

BEVERLY, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex, PCR testing for veterinary diagnostics and biopharmaceutical manufacturing, today announced, it successfully utilized its MiQLab™ System to correctly identify bacteria and determine the presence of antimicrobial resistance (AMR) markers that predict resistance to commonly prescribed first-line veterinary antibiotics.

Key Points: 
  • Dr. Jack Regan, LexaGenes CEO and Founder stated, The results from this study prove that the MiQLab is extremely accurate.
  • We are happy that we are gaining momentum in veterinary diagnostics and expect our technology to eventually be considered a must-have for veterinary hospitals interested in offering best-in-class service.
  • Many veterinarians are unwilling to wait this long for test results as an untreated urinary tract infection can lead to significant complications.
  • *MiQLab Bacterial and AMR Test V2 detects 10 common pathogens and 33 genes and variants that confer resistance to four classes of antimicrobials (beta-lactams, lincosamides, sulfa-TMP, and tetracyclines).

CerbACT Asia Holds Ribbon Cutting to Celebrate New Immuno-oncology Centre of Excellence

Thursday, October 7, 2021 - 10:48am

The opening ceremony held on the 30th September 2021, was attended by distinguished guests virtually and in-person, marking the start of operations and expansion of the precision medicine offer in Asia.

Key Points: 
  • The opening ceremony held on the 30th September 2021, was attended by distinguished guests virtually and in-person, marking the start of operations and expansion of the precision medicine offer in Asia.
  • "Everyone here at CerbACT Asia is fully committed to provide high-quality results to our clients and hope to improve patient outcomes through precision medicine," says Dr George Wei, Managing Director of CerbACT Asia.
  • Together, we offer a broader range of top-notch technologies and services in Asia.
  • CerbACT Asia is an Immuno-Oncology Centre of Excellence that empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research and clinical development strategies.

Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Sunday, October 3, 2021 - 8:30pm

Once an optimal dose and schedule of tasquinimod for the IRd combination is established, an expansion cohort will be recruited to further document the biological activity of tasquinimod in myeloma patients.

Key Points: 
  • Once an optimal dose and schedule of tasquinimod for the IRd combination is established, an expansion cohort will be recruited to further document the biological activity of tasquinimod in myeloma patients.
  • Our preclinical laboratory models suggest that this combination strategy may be a particularly effective way to utilize tasquinimod in myeloma therapy."
  • Tasquinimod has demonstrated a clear therapeutic potentialin preclinical models of multiple myeloma, when used as a single agent and in combination with standard multiple myeloma therapy.
  • Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma.

Phosplatin Therapeutics Appoints Industry Veteran Elizabeth Tallett to Board of Directors

Wednesday, September 29, 2021 - 1:00pm

NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Phosplatin Therapeutics Inc. , a clinical stage pharmaceutical company focused on oncology therapeutics, todayannounced the appointment of Elizabeth Tallett to the company's Board of Directors.

Key Points: 
  • NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Phosplatin Therapeutics Inc. , a clinical stage pharmaceutical company focused on oncology therapeutics, todayannounced the appointment of Elizabeth Tallett to the company's Board of Directors.
  • Ms. Tallett brings a wealth of industry experience to Phosplatin, and the company will benefit from her extensive drug development and commercial insights as it advances its lead therapeutic candidate, PT-112.
  • Ms. Tallett has more than 35 years of experience across strategic leadership and operational roles in worldwide biopharmaceutical companies.
  • She was Principal of Hunter Partners, which advised Phosplatin Therapeutics early in its development.